icon
icon
icon
icon
Upgrade
icon

GSK's drug reduced the risk of death by 42% in a multiple myeloma study.

AInvestTuesday, Dec 10, 2024 1:40 am ET
1min read

GlaxoSmithKline (GSK.US) reported that a study showed its drug belantamab mafodotin reduced the risk of death in patients with multiple myeloma at first relapse or after relapse by 42%.

The study is evaluating belantamab mafodotin in combination with bortezomib plus dexamethasone (BVd) versus daratumumab with bortezomib plus dexamethasone (DVd) as second-line or subsequent therapy for relapsed or refractory multiple myeloma.

The planned interim analysis (DREAMM-7) showed a statistically significant 42% reduction in the risk of death in patients receiving belantamab mafodotin versus the daratumumab-based comparator, with a median follow-up of 39.4 months.

GSK added that, although the median overall survival (mOS) had not been reached for either study group, the expected mOS was 84 months for BVd and 51 months for DVd, according to a statement.

The UK drugmaker also said the belantamab mafodotin combination showed a statistically significant advantage in the key secondary endpoint of minimal residual disease negativity.

The data were presented at the American Society of Hematology annual meeting in San Diego.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.